Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma
Clinical trial NCT05515315 · RECRUITING
Trial details
- NCT number
- NCT05515315
- Sponsor
- Fuzhou General Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-31
- Primary completion
- 2025-05-31
- Enrollment
- 93
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.